A comparison of insulin lispro Mix25™ and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan

Mattoo, Vinod; Miličević, Zvonko; Malone, James; Schwarzenhofer, Maria; Ekangaki, Abie; Levitt, L.K.; Liong, L.H.C.; Rais, Nadeem; Tounsi, H.

doi:10.1016/s0168-8227(02)00202-4

Cited by 78 publications

(53 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, many will need an additional dose of short-acting insulin at predawn. There is some evidence suggesting that use of insulin lispro instead of regular insulin before meals in patients with type 2 diabetes who fast during Ramadan is associated with less hypoglycemia and smaller postprandial glucose excursions (26,27). Again, as emphasized earlier, the overall dosage of medications, especially that of insulin, must be adjusted in conjunction with the weight loss or gain that may occur during Ramadan.…”

Section: Management Of Patients With Type 2 Diabetesmentioning

confidence: 98%

Recommendations for Management of Diabetes During Ramadan

Alarouj

Bouguerra

Buse³

et al. 2005

Diabetes Care

233

231

View full text Add to dashboard Cite

Section: Management Of Patients With Type 2 Diabetesmentioning

confidence: 98%

Recommendations for Management of Diabetes During Ramadan

Alarouj

Bouguerra

Buse³

et al. 2005

Diabetes Care

233

231

View full text Add to dashboard Cite

“…A comparison of insulin lispro Mix25 (25% short-acting lispro/75% intermediate-acting lispro protamine) with human insulin 30/70 (30% short-acting soluble human insulin/70% intermediate-acting neutral protamine Hagedorn [NPH]) during Ramadan found that overall glycaemia was significantly lower for patients on insulin lispro Mix25 (p = 0.004), with the greatest between-treatment difference evident before and after iftar [54]. Similarly, in another study insulin lispro Mix50 (50% lispro/50% lispro protamine) in the evening and regular human insulin with NPH (30:70) in the morning improved glycaemic control without increasing the incidence of hypoglycaemic events compared with regular human insulin with NPH (30:70) given twice daily [55].…”

Section: Insulin Treatment For T2dmmentioning

confidence: 99%

Diabetes and Ramadan: Practical guidelines

Hassanein

Alarouj

Hamdy

et al. 2017

Diabetes Research and Clinical Practice

277

357

View full text Add to dashboard Cite

“…• Insulin aspart 70/30 versus NPH/regular 70/30-3 parallel-arm trials 31,33,34 and 3 crossover trials [35][36][37] • Insulin lispro 75/25 versus NPH/regular 70/30 or NPH/regular 50/50-9 randomized crossover studies [37][38][39][40][41][42][43][44][45] and 1 retrospective observational study 28 • Insulin lispro 50/50 versus NPH/regular 70/30 or NPH/ regular 50/50-3 randomized crossover studies 38,41,46 and 1 parallel-arm study 47 The studies varied considerably in therapy administration methods, dosing schedules, and duration.…”

Section: Premixed Insulin Analogues Versus Premixed Human Insulinmentioning

confidence: 99%

AHRQ's Comparative Effectiveness Research on Premixed Insulin Analogues for Adults with Type 2 Diabetes: Understanding and Applying the Systematic Review Findings

Qayyum¹,

Greene²

2011

JMCP

View full text Add to dashboard Cite

experience includes numerous meta-analytic studies on treatments for conditions such as type 2 diabetes, hypertension, acute coronary syndromes, and the effectiveness of continuing medical education. His research has been supported by the Agency for Healthcare Research and Quality and the National Institutes of Health. He serves as Associate Editor of the Journal of Hospital Medicine and is a member of the Society of Hospital Medicine, the American Heart Association, and the American College of Physicians. ) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. PRIME ® designates this Journal-Based CME activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Pharmacist Accreditation StatementThis curriculum has been approved for 2.5 contact hours by PRIME ® . PRIME ® is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The universal program number for this activity is 0255-0000-11-004-HO1-P. This learning activity is Knowledge-based. Nurse Accreditation Statement PRIME Education, Inc. (PRIME ® ) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. PRIME ® designates this activity for 2.5 contact hours. Case Manager Accreditation StatementThe Commission for Case Manager Certification designates this educational activity for 2.0 contact hours for certified case managers. AHRQ's Comparative Effectiveness Research on Premixed Insulin Analogues for Adults with Type 2 Diabetes: Understanding and Applying the Systematic Review Findings Credit Instructions:In order to receive CME/CE credit for this program, you must: 1. Review this program in its entirety 2. Access www.ce.effectivehealthcare.ahrq.gov/credit and enter program code CER1 3. Complete the post-test (70% passing score) and evaluation online 4. Print your CME/CE statement immediately following the evaluation DISCLOSURESQayyum produced this program under contract with PRIME Education, Inc. (PRIME ® ). Greene is an employee of PRIME ® . The authors report no financial or other conflicts of interest related to the subjects in this report. Mooradian, Jarvis, Gunning, and Valdez report no financial or other conflicts of interest related to the subjects in this report.Brixner reports consultant relationships with Novo Nordisk, Novartis, and Abbott Laboratories, and grant funds paid to her institution from Bristol-Myers Squibb and Novo Nordisk. Campbell reports participation in the speakers bureau for Eli Lilly. Neumiller reports grant funds paid to his institution from Amylin, Johnson & Johnson, Merck, and Novo Nordisk. Quilliam reports grant funds paid to his institution from Takeda and Ortho-McNeil Janssen. ACKNOWLEDGEMENTSThe authors acknowledge Diana I. Brixner, RPh, PhD, and Karen M. Gunning, PharmD, of the University of Utah Departme...

show abstract

A comparison of insulin lispro Mix25™ and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan

Cited by 78 publications

References 13 publications

Recommendations for Management of Diabetes During Ramadan

Recommendations for Management of Diabetes During Ramadan

Diabetes and Ramadan: Practical guidelines

AHRQ's Comparative Effectiveness Research on Premixed Insulin Analogues for Adults with Type 2 Diabetes: Understanding and Applying the Systematic Review Findings

Contact Info

Product

Resources

About